Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lesko

Showing results (801-810 of 1,126) with videos related to

Pageof 113
Sort By:
Drug Discovery Today|February 8, 2020
Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicineDarshan Mehta, Ryley Uber, Taylor Ingle, et al.
Journal of Clinical Pharmacology|February 28, 2018
Regulatory Perspectives in Pharmacometric Models of OsteoporosisKumpal Madrasi, Fang Li, Myong-Jin Kim, et al.
Pharmaceutical Research|January 12, 2002
Bioavailability and bioequivalence: an FDA regulatory overviewM L Chen, V Shah, R Patnaik, et al.
Investigational New Drugs|June 28, 2022
Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trialM Mego, D Svetlovska, De Angelis V, et al.
Annals of Family Medicine|May 14, 2014
The future role of the family physician in the United States: a rigorous exercise in definitionRobert L Phillips, Stacy Brundgardt, Sarah E Lesko, et al.
Pediatrics|August 14, 2013
Electronic health record identification of nephrotoxin exposure and associated acute kidney injuryStuart L Goldstein, Eric Kirkendall, Hovi Nguyen, et al.
Journal of Clinical Pharmacology|January 18, 2008
Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006Yaning Wang, A Venkatesh Bhattaram, Pravin R Jadhav, et al.
Stem Cell Reports|March 5, 2019
SQSTM1/p62-Directed Metabolic Reprogramming Is Essential for Normal NeurodifferentiationJavier Calvo-Garrido, Camilla Maffezzini, Florian A Schober, et al.
Implementation Science Communications|March 20, 2021
Evaluation of a multidisciplinary lipid clinic to improve the care of individuals with severe lipid conditions: a RE-AIM framework analysisLaney K Jones, Megan McMinn, David Kann, et al.
European Journal of Epidemiology|September 18, 2024
Cohort profile update: the Johns Hopkins HIV clinical cohort, 1989-2023Catherine R Lesko, Anthony T Fojo, Jeanne C Keruly, et al.
Pageof 113

Showing results (801-810 of 1,126) with videos related to

Sort By:
Pageof 113
Drug Discovery Today|February 8, 2020
Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicineDarshan Mehta, Ryley Uber, Taylor Ingle, et al.
Journal of Clinical Pharmacology|February 28, 2018
Regulatory Perspectives in Pharmacometric Models of OsteoporosisKumpal Madrasi, Fang Li, Myong-Jin Kim, et al.
Pharmaceutical Research|January 12, 2002
Bioavailability and bioequivalence: an FDA regulatory overviewM L Chen, V Shah, R Patnaik, et al.
Investigational New Drugs|June 28, 2022
Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trialM Mego, D Svetlovska, De Angelis V, et al.
Annals of Family Medicine|May 14, 2014
The future role of the family physician in the United States: a rigorous exercise in definitionRobert L Phillips, Stacy Brundgardt, Sarah E Lesko, et al.
Pediatrics|August 14, 2013
Electronic health record identification of nephrotoxin exposure and associated acute kidney injuryStuart L Goldstein, Eric Kirkendall, Hovi Nguyen, et al.
Journal of Clinical Pharmacology|January 18, 2008
Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006Yaning Wang, A Venkatesh Bhattaram, Pravin R Jadhav, et al.
Stem Cell Reports|March 5, 2019
SQSTM1/p62-Directed Metabolic Reprogramming Is Essential for Normal NeurodifferentiationJavier Calvo-Garrido, Camilla Maffezzini, Florian A Schober, et al.
Implementation Science Communications|March 20, 2021
Evaluation of a multidisciplinary lipid clinic to improve the care of individuals with severe lipid conditions: a RE-AIM framework analysisLaney K Jones, Megan McMinn, David Kann, et al.
European Journal of Epidemiology|September 18, 2024
Cohort profile update: the Johns Hopkins HIV clinical cohort, 1989-2023Catherine R Lesko, Anthony T Fojo, Jeanne C Keruly, et al.
Pageof 113